Tempus AI, Inc.
TEM
Rang în acțiuni
#1886
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Preț acțiune
$64.29
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$11.28B
Schimbare (1 zi)
-9.62%
Schimbare (1 an)
-26.76%
Țară
US
Tranzacționează Tempus AI, Inc. (TEM)
Categorie
Healthcare
Marja operațională pentru Tempus AI, Inc. (TEM)
Marja operațională la October 2026 TTM: -19.76%
Conform celor mai recente rapoarte financiare și prețului acțiunilor Tempus AI, Inc., marja operațională curentă (TTM) este -19.76%. La finalul anului 2023, compania avea o marjă operațională de -36.87%.
Istoricul marjei operaționale pentru Tempus AI, Inc. din 2019 până în 2026
Marja operațională la sfârșitul fiecărui an
| An | Marja Operațională | Schimbă |
|---|---|---|
| 2026 (TTM) | -19.76% | -80.17% |
| 2024 | -99.67% | 170.33% |
| 2023 | -36.87% | -55.46% |
| 2022 | -82.78% | -12.42% |
| 2021 | -94.52% | -8.14% |
| 2020 | -102.90% | -46.69% |
| 2019 | -193.02% | 0.00% |
Marja operațională pentru companii similare sau concurente
| Companie | Marja Operațională | Diferență în marja operațională | Țara |
|---|---|---|---|
| 12.70% | -100.64% |
US
|
|
| 74.94% | -103.79% |
AU
|
|
| 3.33% | -100.17% |
US
|
|
| -14.33% | -99.27% |
US
|
|
| 0.00% | - |
US
|
Ce este marja operațională a unei companii?
Marja operațională este un indicator esențial pentru evaluarea profitabilității unei companii. Marjele operaționale mai mari sunt de obicei mai bune, deoarece arată că o companie poate vinde produsele sau serviciile sale la prețuri mult mai mari decât costurile de producție. Marja operațională se calculează împărțind profitul companiei la venitul său.